iiinova — where your digital self keeps evolving

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 21/09/2026

So much important information in this survey. "When the world doesn’t invest in women’s health, that dramatically impacts how they can show up at work, at home, and in their communities" #womenshealth www.pivotal.com/articles/gal...

001

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 30/05/2026

#ASCO26 Improved PFS and OS with teclistamab monotherapy vs PVd or Kd in RRMM after 1-3 prior therapies. Infection prevention still key. #myeloma Published simultaneously in NEJM. #MMSM #Medsky www.cancercommunicator.com/asco26-news-...

020

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 29/05/2026

#ASCO26 WU-KONG28: sunvozertinib significantly improved PFS vs carboplatin–pemetrexed (median 10.3 vs 7.5 mo; HR 0.65; P<.001) in 1st-line advanced nonsquamous #NSCLC w/ EGFR exon 20 insertion mutation. Published sim in @nejm.org www.cancercommunicator.com/asco26-first...

010

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 28/05/2026

Less than a day away from #ASCO26. A few notable oral abstract sessions tomorrow: ● Metastatic NSCLC, 1 PM Hall D2 ● Heme - Plasma cell dyscrasia, 2:45 PM S100a ● GU – Kidney and Bladder, 2:45 PM Arie Crown ● Gyn, 2:45 PM S100bc cancercommunicator.com

010

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 25/05/2026

The new loan caps in the One Big Beautiful Bill Act will limit access to the professions that keep people alive. New editorial on what this does to the healthcare providers pipeline. #MedSky #HealthPolicy #StudentLoans www.cancercommunicator.com/obbba-loan-c...

000

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 25/05/2026

Gift article: "Pope Leo XIV on Monday set out a sweeping vision for corporate executives, politicians and individuals who will shape and be shaped by the future of artificial intelligence, warning leaders to safeguard humanity from A.I.’s most disruptive effects" #AI www.nytimes.com/2026/05/25/w...

031

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 10/03/2026

"There was a palpable sense of anxiety, if not fear." Rick Pazdur, MD talks candidly about today's FDA and leaving the agency after 26 yrs of building their #oncology program. Check out Ep27 of #OncologyUnscripted at cancercommunicator.com/ou-pazdur #FDA #MedSky #OncSky

020

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 10/02/2026

These charts tell a story..."Industry analysts estimate that China now accounts for 70–95% of the global supply chain for many essential pharmaceutical products...In 2024, Chinese biotechnology firms developed > 1,250 new drugs, surpassing the European Union and approaching the US total of ~1,440"

000

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 23/12/2025

JAMA Most views articles of 2025. #MEDSKY bit.ly/3KZh7CK

010

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 06/12/2025

#ASH25 (Abs 47): Encouraging early results (N=21, median age 70 y) from ph2 SAVE trial of all-oral regimen: revumenib + decitabine/cedazuridine + venetoclax in ND NPM1- or KMT2A-mutated AML. 86% ORR, 81% CR/CRh. #Medsky #cansky #oncsky #AML www.cancercommunicator.com/oral-menin-b...

031

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 17/10/2025

Lots of exciting data at #ESMO25. Here are the 3 Presidential Symposia presentations. Tomorrow: DESTINY-Breast11 (high-risk HER2+ eBC), DESTINY-Breast05 (high-risk HER2+), KEYNOTE-05 (MIBC), KEYNOTE-B96 (ovarian). #BCSM #Bladdercancer #gusm #ovariancancer #gynsm

010

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 17/10/2025

It’s here! #ESMO25 kicks off today — Packed agenda with important data, some practice changing. Check out studies that will presented in the 3 Presidential Symposia 👇

010

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 12/09/2025

What’s behind the rise in GI cancers among young adults? Dr Marshall explores this in our latest #OncologyUnscripted. 🎥 Watch here: clinicalcaresolutions.net/activities/o... #GIcancer #CancerCare #MedSky #OncSky #CanSky #CRC

161

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 08/09/2025

At #WCLC25 results of #FLAURA2 showed a 47.5 mo mOS w/ osimertinib+chemo in pts w/ advanced EGFRm+ NSCLC vs 37.6 with osi monotherapy. Benefit seen across subgroups. Longer chemo-free period with combo. #LCSM #LungCancer #NSCLC #oncsky #cansky

031

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 31/08/2025

"since the widespread adoption of generative AI, early-career workers (ages 22-25) in the most AI-exposed occupations have experienced a 13 percent relative decline in employment even after controlling for firm-level shocks." digitaleconomy.stanford.edu/wp-content/u...

000

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 18/07/2025

ODAC voted against the overall benefit-risk of belantamab mafodotin combinations (BVd and BPd) not disputing the drug's efficacy, but citing toxicity and a missed opportunity to optimize dose along with inadequate enrollment of the US population. #MMSM #FDA www.youtube.com/live/CLhBI3U...

010

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 12/06/2025

The latest episode of Oncology Unscripted with John Marshall is live! We recorded this one at #ASCO25. Enjoy! clinicalcaresolutions.net/activities/o...

021

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 01/06/2025

Perioperative durvalumab+FLOT in pts w/ resectable GC/GEJC improved EFS vs pbo+FLOT overall and across subgroups and ⬆️pCR rates in the #MATTERHORN study (N=948) presented at #ASCO2025 plenary. New SOC. Published simultaneously in @nejm.org #cansky #oncsky #gism

010

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 01/06/2025

SERENA-6 results presented at #ASCO25 plenary and published simultaneously in @nejm.org switching from AI to oral SERD camizesrant with continued CDK4/6 based on mESR1 ctDNA improved PFS overall and across subgroups and delayed time to QOL deterioration #cansky #oncsky #bcsm

040

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 01/06/2025

Ph 3 VERIFY study (part1a) presented by kuykendallmd.bsky.social during the #ASCO25 plenary: weekly rusfertide improved clinical response, maintained Hct <45%, and reduced phlebotomy need vs pbo w/ ⬆️ QOL in pts with polycythemia vera. Benefit across subgroups. New SOC #cansky #oncsky #hemesky #PV

030

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 01/06/2025

#NIVOPOSTOP adjuvant nivolumab+radiochemotherapy vs radiochemotherapy alone in resected locally advanced #HNSCC <75y at high risk of relapse: 3y DFS 63.1% vs 51.5% HR=0.76 P=.034 #cansky #oncsky #medsky #asco25 #ascoplenary

050

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 01/06/2025

#ATOMIC mFOLFOX6 vs mFOLFOX6+atezolizumab in stage III dMMR colon cancer yields improved DFS (3y 76.6% vs 86.4%) #ascoplenary #asco25 #cansky #oncsky

050

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 01/06/2025

Durable reponses with Allo-316 allogeneic CD70 CAR T-cell therapy in advanced clear cell RCC presented by Dr Srour at #ASCO25 phase 1b TRAVERSE study #RCCsm #cansky #oncsky

042

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 22/05/2025

This Isn’t Just About Harvard-It’s About All of Us. "You can understand why this is threatening to what is truly been special about United States education, and that is the freedom of speech, the freedom of thought, the challenging of each other..." bit.ly/3YSjZFi #medsky #academicsky

000

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 15/05/2025

SURMOUNT-5: for obesity but w/o diabetes, tirzepatide superior to semaglutide wrt reduction in body weight and waist circumference at wk 72. N=751 meant % weight change -20.2% vs -13.7% (P<.001). High rates of GI AEs w/ both agents. #medsky #obesitymedicine

000

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 15/04/2025

Boston hospitals will be hit hard from the government's retaliation against Harvard. These 5 hospitals collectively received >$1.56 billion in NIH in 2024. This is not okay. Harvard and affiliates to excellent cancer research and patients will be impacted @medsky www.thecrimson.com/article/2025...

120

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 06/04/2025

#HandsOff in Seattle. One of the many across our state and around the country.

021

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 03/04/2025

Just a reminder this is what HHS covers. The workforce has been shrunk from 82000 to 62000 without much care for the impacts on Americans. #medsky #cansky #oncsky #CDC #HHS

034

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 11/01/2025

#Alliance25 is in the books. It was so much fun to present with these smart and lovely humans! #Medsky #AIethics

150

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 09/01/2025

What an amazing presentation by Dr Sheppard at #Alliance25. #AI is not pulling data out of thin air, it echos what it's been given and presents it as fact which has some serious and real consequences #Medsky #CME

040

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 17/12/2024

Notable 2024 articles by @nejm.org editors. GLP-1 receptor agonists had a definite impact this year #medsky #obesitymedicine. Immunotherapy studies in HL and early-stage TNBC make the #onsky list. #bcsm #lymsm

030

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 10/12/2024

#ASH24 LBA2 Fenske E4151 MCL pts in first remission who were MRD negative at 10-6 by clonoSEQ did not benefit from auto-HCT. In exploratory analysis pts who were MRD+ after induction and converted to MRD-neg (10-6) post auto-HCT showed OS and PFS benefit vs those who did not convert. #lymsm #oncsky

020

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 10/12/2024

Standardized oncology social media hashtags from jamanetwork.com/journals/jam... #oncsky #oncsm #medsky #hemesky

0132

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 09/12/2024

#ASH24 Plenary Wuliji- prospective: SDOH on receipt of allo-HCT for AML or MDS. Area-level lower education and higher surrogates of poverty associated with higher mortality without transplant and reduced chance to receive transplant. Once patients receive transplant simila4 outcomes #hemesky #oncsky

000

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 08/12/2024

#ASH24 Plenary Abs 5 Kuter-ph3 LUNA3 in heavily pretreated adults w/ITP BTKi rilzabrutinib 23% durable platelet response. Improved secondary EPs. QOL better in responders and nonresponders. #ITP #hemesky

031

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 08/12/2024

#ASH24 plenary Abs 4 Liu-Preclinical mouse studies, xenograft cancer models, and retrospective trial data suggests ketogenic diet enhances #CART via beta-hydroxybuterate (BHB). Clinical trials underway #hemesky #oncsky

010

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 08/12/2024

#ASH24 plenary-a3: Dei-Adomakoh PIVOT trial (pbo controlled)-hydroxyurea treatment 20 mg/kg/d significantly reduced painful vaso-occlusive events and led to fewer hospitalization in adults and children with #HbSC. 22% increase in DLT and 1 death w/ HU simult published in NEJM Evidence #hemesky

000

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 08/12/2024

#ASH24 #Plenary Abst2 Zhang Age-related attrition of the megakaryocytic niche and associated PF4 downregulation central to HSC aging. #hemesky

000

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 08/12/2024

#ASH24 plenary_1 Rau New SOC-Blin+CT increases DFS in ND standard-risk pediatric B-ALL AALL1731 compared with CT with a 61% reduction in DFS. Blin arm associated with increased risk of sepsis and catheter-related infections. #lymsm #oncsky #hemesky

030

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 08/12/2024

#ASH24 254 Giri MRD-adapted treatment duration-NDMM Tx w/QUAD+ASCT monitored with serial marrow-based MRD by NGS. Pts w/NO HRCA and sustained MRD negativity have very low risk of progression or MRD resurgence despite no ongoing Tx #mmsm #oncsky #medsky #hemesky @oncoalert.bsky.social

061

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 08/12/2024

#ASH24 255 Hofmeister-Improved seroprotection with 3 high-dose influenza vaccines vs 1 in pts with plasma cell dyscrasia. Ongoing dara lowers odds of achieving seroprotection in pts receiving 1 but not 3 vaccines #mmsm #onsky #medsky #hemesky @oncoalert.bsky.social

052